BioCentury
ARTICLE | Company News

Voyager gets $165M up front from Neurocrine for gene therapies

January 29, 2019 8:41 PM UTC

Voyager Therapeutics Inc. (NASDAQ:VYGR) gained $3.08 (38%) to $11.12 on Tuesday after it said it will receive $165 million up front from Neurocrine Biosciences Inc. (NASDAQ:NBIX) in exchange for a license to four of Voyager's neurology gene therapy programs. Voyager is eligible for $1.7 billion in milestones across the four programs.

Neurocrine gains rights to develop and commercialize VY-AADC, which is in the Phase II RESTORE-1 trial to treat Parkinson's disease; VY-FXN01, which is in preclinical testing to treat Friedreich ataxia; plus two programs yet to be determined...